Autoimmune Disease Diagnostics Market Size, Report, 2032

marketinsights
Email: kishorbombexox@gmail.com

posted on 1 week ago updated on 1 second ago

25
views

Meticulous Research^®—a leading global market research company, published a research report titled, Autoimmune Disease Diagnostics Market Size, Share, Forecast, & Trends Analysis By Product (Reagents, Kits, Assays, Instruments), Test Type (ANA, CRP, ESR, Rheumatoid Factor, Routine Test), Disease Type (Systemic, Localized) - Global Forecast to 2031.’

According to this latest publication from Meticulous Research^®, the autoimmune disease diagnostics market is expected to reach $11.45 billion by 2032, at a CAGR of 7.5% during the forecast period. The increasing prevalence of autoimmune disorders, the growing emphasis on early diagnosis, and the rising awareness regarding autoimmune diseases are some of the factors driving the growth of this market.

However, difficulties in diagnosing autoimmune diseases restrain the growth of this market. Emerging economies and increasing investments & funding in the autoimmune disease diagnostics space are expected to generate growth opportunities for the players in this market. Moreover, the unfavorable reimbursement scenario and high rate of delayed diagnosis or misdiagnosis are major challenges for market growth.

Key Players

The key players operating in the autoimmune disease diagnostics market are Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson, and Company (U.S.), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Grifols, S.A. (Spain), and Creative Diagnostics (U.S.).

Autoimmune Disease Diagnostics Market: Future Outlook

The autoimmune disease diagnostics market is segmented based on product, test type, disease type, end user, and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on product type, the autoimmune disease diagnostics market is segmented into reagents, assays & kits; software & services; and instruments. In 2024, the reagents, assays, & kits segment is expected to account for the largest share of 84.0% of the autoimmune disease diagnostics market. The large market share of this segment is attributed to factors such as the recurrent use of reagents & kits, the availability of antibodies and other reagents for several test applications, and the increasing number of launches & approvals.

Based on test type, the autoimmune disease diagnostics market is segmented into antinuclear antibodies (ANA), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor, immunoglobulins, routine blood tests, and other test types. In 2024, the antinuclear antibodies (ANA) segment is expected to account for the largest share of 29.4% of the autoimmune disease diagnostics market. The large share of this segment is attributed to factors such as the high prevalence of autoimmune diseases, the high accuracy & simplicity of the ANA test for autoimmune disease testing, and the need for early disease diagnosis to prevent morbidity & mortality.

Based on disease type, the autoimmune disease diagnostics market is segmented into systemic autoimmune diseases and organ-specific autoimmune diseases. In 2024, the systemic autoimmune diseases segment is expected to account for the larger share of the autoimmune disease diagnostics market. The large market share of this segment is attributed to the high prevalence of systemic autoimmune diseases such as multiple sclerosis, Type-1 diabetes, and systemic lupus erythematosus.

Based on end user, autoimmune disease diagnostics is segmented into diagnostic laboratories, hospitals & clinics, and academic & research institutes. In 2024, the hospitals segment is expected to account for the largest share of the autoimmune disease diagnostics market. The large market share of this segment is attributed to the high volume of tests performed in hospitals & clinics and the high demand for early autoimmune disease diagnosis and treatment.

Geographical Review

This research report analyzes major geographies and provides a comprehensive analysis of the market in North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), Latin America, and the Middle East & Africa. In 2024, North America is expected to account for the largest share of 39.6% of the autoimmune disease diagnostics market, followed by Europe and Asia-Pacific. North America’s major market share is attributed to factors such as high healthcare expenditure, high prevalence of autoimmune diseases, increased awareness among patients regarding autoimmune diseases, and increased funding and investments towards R&D of autoimmune diseases.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5405

Key questions answered in the report:

Which are the high-growth market segments in terms of product, test type, disease type, end user, and region/country?
What was the historical market size for autoimmune disease diagnostics across the globe?
What are the market forecasts and estimates for 2024–2031?
What are the major drivers, restraints, opportunities, and challenges in the global autoimmune disease diagnostics market?
Who are the major players in the autoimmune disease diagnostics market?
How is the competitive landscape, and who are the market leaders in the global autoimmune disease diagnostics market?
What are the recent developments in the global autoimmune disease diagnostics market?
What strategies are adopted by the major players in the global autoimmune disease diagnostics market?
What are the geographical trends and high-growth regions/countries?